Kineret For Rheumatoid Arthritis

 Kineret: Availability in India

Patients with moderately to highly active rheumatoid arthritis who have received at least one disease-modifying antirheumatic medication (DMARD) but failed to manage signs and symptoms or delay the course of structural damage are prescribed kineret injection. These patients must be 18 years of age or older. 

It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease (NOMID). 

It is provided by Indian Pharma Network, and you may purchase it there at a fair price. 

 Dosage and Administration 

There is a 100 mg/0.67 mL subcutaneous injectable solution available. Doses between 20 and 100 mg are possible with a graduated syringe. Kineret is injected subcutaneously, or beneath the skin, to deliver the medication. Kineret 100 mg once daily is the recommended dosage for treating rheumatoid arthritis, and it should be taken roughly the same time each day. The dosage for familial Mediterranean fever, Still's illness, and CAPS is based on the patient's weight and the severity of the condition. Patients with CAPS must be at least 8 months old and 10 kg in weight to receive treatment. Take 100 mg of COVID-19 once a day for 10 days.      

KFDA Approved 

Kineret was given the go-ahead to treat RA and Cryopyrin-Associated Periodic Syndromes (CAPS) on November 14, 2001. Human interleukin-1 receptor antagonist (IL-1Ra) is marketed as Kineret (anakinra) and is available in the recombinant, non-glycosylated form. A single methionine residue has been added to the amino terminus of Kineret, which makes it different from native human IL-1Ra. Kineret has a molecular weight of 17.3 kilodaltons and 153 amino acids. It is created using a bacterial expression system from E. coli and recombinant DNA technologies.

Storage

Glass single-use syringes with 27 gauge needles are used to administer Kineret. Each prefilled glass syringe has a 0.67 mL volume and weighs 100 milligrammes of anakinra. Anakinra is included in 100 milligrams of the whole syringe. A 4 x 7 syringe dispensing pack with 28 syringes is available to administer Kineret.

 One should store Kineret between 2 and 8 degrees Celsius or 36 and 46 degrees Fahrenheit. It must be protected from light, not torefrozen, or disturbed.

Mechanism of Action

Kineret (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). Immunosuppressive drugs work by reducing immune system function. An artificial replica of a human protein called "human interleukin 1 receptor antagonist," anakinra blocks the body's interleukin 1 receptors. High levels of this interleukin production are present in rheumatoid arthritis patients, which causes joint inflammation and, ultimately, joint damage. Additionally, it fuels the inflammation connected to CAPS, familial Mediterranean fever, and Still's illness. There is no binding site left because anakinra prevents the action of interleukin 1 by attaching to the receptors where interleukin 1 would ordinarily attach. The indications and symptoms of many ailments are eventually relieved.

Kineret injection is offered for a reasonable and cost-effective price, and for more information on Kineret cost, contact us at Indian Pharma Network | +91 93100 90915(Toll-Free).

Adverse Reactions

Rheumatoid Arthritis (RA) The most frequent side effects (incidence 5%) are injection site reactions, rheumatoid arthritis aggravation, upper respiratory tract infections, headaches, nausea, diarrhea, sinusitis, arthralgia, and stomach discomfort.

NOMID- The most frequently reported adverse effects (incidence >10%) during the first six months of treatment were injection site reactions, headaches, vomiting, arthralgia, pyrexia, and nasopharyngitis.

Only with a prescription can one receive Kineret, and only a licensed physician should initiate and oversee treatment. The kineret injection is available fairly and cheaply 

Drug Interaction

There have been no studies on medication interactions involving humans. The clearance or toxicologic profiles of either drug did not significantly change after methotrexate and Kineret administration to rats in toxicologic and toxicokinetic studies. 

TNF Blocking Agents: Studies have shown that patients taking concurrent Kineret and etanercept therapy have a greater incidence of serious infections than patients getting etanercept alone. In 2% of individuals receiving Kineret and etanercept simultaneously, neutropenia (ANC 1 x 109/L) developed. Combining Kineret with TNF-blocking drugs is not recommended.

Kineret can only be obtained with a prescription; only a qualified medical professional should start and manage treatment. The cost of Kineret injection is reasonable and accessible; for additional details, 

Use In Specific Population 

• When a young person has NOMID, Kineret is advised for geriatric use. Due to the higher prevalence of infections in the senior population as a whole, care should be taken when treating the elderly.
• Renal dysfunction: Because this medication is believed to be mostly removed through the kidneys, patients with impaired renal function may be more vulnerable to negative drug responses. 

Kineret should only be used under the supervision of a licensed medical professional, and a prescription is required to obtain it. 

Warnings and Precautions

• Stop using the RA medication if a serious infection develops. Patients with NOMID should weigh the potential risks of quitting Kineret therapy against the possibility of a NOMID flare. Starting Kineret shouldn't be done by patients who have active infections. 
• Combining it with drugs that block tumor necrosis factor (TNF) is not recommended.
• There have been documented cases of angioedema and anaphylactic reactions, among other hypersensitivity events. 
• Kineret treatment has not been demonstrated to affect the development of cancer or active or persistent infections.
• Live vaccines shouldn't be given combined with Kineret.
•  Before beginning Kineret therapy, neutrophil levels should be assessed every three months while on Kineret and then every six months for up to a year afterwards. 
• Kineret injection is priced fairly and rationally; for more information on the medication and Kineret 100 mg/0.67ml, 

Tibsovo: Indication and Usage

 Tibsovo: Indication and Usage

Tibsovo is an FDA-approved isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat adult patients who have a susceptible IDH1 mutation as detected by an FDA-approved test with:

AML (Acute Myeloid Leukaemia) is a kind of blood cancer.

AML patients over the age of 75 who have comorbidities that prevent vigorous induction chemotherapy from being administered AML that has relapsed or is refractory

Cholangiocarcinoma, either localized or metastatic

 Patients suffering from locally advanced or metastatic cholangiocarcinoma who have previously been treated

This effective medication is available on the market and can be obtained from any reputable dealer. Furthermore, the Tibsovo price in India is tiny and incredibly reasonable, making it simple to incorporate into therapy. 

Tibsovo: Dosage and Administration

Tibsovo 250 mg Tablets are available. Tibsovo should be taken once a day orally until disease progression or severe toxicity occurs.

Tibsovo can be administered with or without food. Tibsovo should not be used with a high-fat meal due to an increase in Tibsovo concentration [see Warnings and Precautions (5.2) and Clinical Pharmacology]. Tibsovo pills should not be crushed or divided. Tibsovo pills should be taken orally at the same time every day. If a Tibsovo dose is vomited, do not replace it; rather, wait until the next scheduled dose is due. If a Tibsovo dose is missed or not taken on time, it should be given as soon as possible and minimum 12 hours before the next scheduled dose. Return to your regular schedule the next day. Do not take two doses within 12 hours of each other. 

Tibsovo: Warnings and Precautions 

Electrocardiograms and electrolytes should be checked for QTc interval prolongation. If QTc interval prolongation occurs, reduce or pause the dose, then resume the dose or discontinue Tibsovo permanently.

Guillain-Barre Syndrome (GBS): Keep a look out for indications and symptoms of new motor and/or sensory impairments in patients. Quit Tibsovo for good if you have Guillain-Barré syndrome.

This powerful pharmaceutical is on the market and may be obtained from any respectable vendor. Furthermore, the Tibsovo price in India is economical, making it simple to incorporate it into treatment. 

Tibsovo: Drug Interaction

Strong or moderate CYP3A4 inhibitors: Reduce TIBSOVO dosage when using strong CYP3A4 inhibitors. Patients should be closely watched for signs of QTc interval prolongation.

 Inducers of CYP3A4: Avoid using TIBSOVO (7.1, 12.3) simultaneously.

If you have sensitive CYP3A4 substrates, avoid using TIBSOVO (7.2, 12.3) at the same time.

Avoid taking QTc prolonging medications with TIBSOVO. Healthcare professionals should monitor the patients for an increased risk of QTc interval prolongation if coadministration is unavoidable.

If someone develop signs and symptoms of differentiation syndrome, the healthcare provider may treat the patient with a corticosteroid medicine or a medicine called hydroxyurea and may monitor you in the hospital.

You can easily buy Tibsovo tablets from India at a lower cost through Indian Pharma Network at a more reasonable and pocket-friendly price. We are the most dependable and trustworthy generic pharmaceutical suppliers in India. You can visit us at 

Tibsovo: Adverse Reactions

Although the price of Tibsovo is reasonable, the following drug interactions must be understood before using the drug. Inquire with your doctor for further information.

The most common adverse symptoms (20%) in AML patients were fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, and ECG. QT prolongation symptoms include rash, cough, decreased appetite, myalgia, constipation, and pyrexia.

The most common laboratory abnormalities (20%) in AML patients were hemoglobin decrease, calcium decrease, sodium decrease, magnesium decrease, uric acid decrease, potassium decrease, alkaline phosphatase decrease, aspartate aminotransferase decrease, phosphate decrease, and creatinine decrease. 

The most common side effects (15%) in patients with cholangiocarcinoma were fatigue, nausea, stomach discomfort, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash.

The most common laboratory abnormalities in cholangiocarcinoma patients (10%) were reduced hemoglobin, increased aspartate aminotransferase, and high bilirubin.

Tibsovo: Mechanism of Action

Ivosidenib is a small molecule inhibitor that prevents the mutant isocitrate dehydrogenase 1 (IDH1) enzyme from working. Susceptible IDH1 mutations in AML patients are those that result in increased 2-hydroxyglutarate (2-HG) levels in leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at ivosidenib concentrations sustainable at the recommended dosage using validated methods. The R132H and R132C alterations are the most common in AML patients. 

Ivosidenib inhibited selected IDH1 R132 mutants in vitro at significantly lower dosages than wild-type IDH1. In mouse xenograft models of AML with an IDH1 mutation, ivosidenib inhibited the mutant IDH1 enzyme, lowering 2HG levels and increasing myeloid growth in vitro and in vivo. In blood samples from patients with AML with mutant IDH1, ivosidenib reduced ex-vivo 2-HG levels, blast counts, and the fraction of mature myeloid cells. 

Tibsovo: Description about the drug

The chemical formula is C28H22ClF3N6O3, and the molecular weight is 583.0 g/mol. In aqueous solutions with pH values ranging from 1.2 to 7.4, ivosidenib is largely insoluble.

Tibsovo (ivosidenib) film-coated 250 mg tablets are available for oral use. Colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate are among the inactive ingredients in each tablet. The tablet coating contains FD&C blue #2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin. 

The drug can be obtained from any generic and innovative provider who has a license to do so under a valid and recognized prescription and who follows the relevant regulations. Indian Pharma Network is one of the most trusted and dependable generic pharmaceutical suppliers, and you can buy Tibsovo online from us at extremely low prices.

All about Atriance Injection

 Atriance: Indication 

Atriance is a cancer drug that is sold under the brand name Nelarabine under a valid and recognized prescription. Patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) whose illness has not responded to or relapsed after treatment with at least two chemotherapy regimens are advised to use Nelarabine. The evidence to support these indications is based on scant data due to the tiny patient populations in these disease situations. 

Nelarabine injection in India is available and can be purchased among reliable suppliers like Indian Pharma Network at reasonable prices. To know more about the drug, you can call us at +91 93100 90915.

Atriance: Dosage and Administration 

It comes in vials as Nelarabine 250 mg. Regular monitoring of complete blood counts, including platelets, is required and only a doctor with training in the use of cytotoxic agents may supervise the administration of Nelarabine. 

• Adults and teenagers (who have reached the age of 16):- 
• For adults and adolescents 16 years of age and older, a dose of 1,500 mg/m2 of Nelarabine given intravenously for two hours on days 1, 3, and 5 and repeated every 21 days is advised. 
• Adolescents and children (under 21 years old) 

Nelarabine should be delivered intravenously by dripping the vein over an hour daily for five days in a row, repeated every three and a half weeks, to children and adolescents (age 21 and under). 

Atriance: Adverse Drug Reactions 

Based on data from 103 adults and 84 pediatric patients, the safety profile from pivotal clinical studies at the indicated doses of Atriance Nelarabine in adults (1,500 mg/m2) and children (650 mg/m2) is based. Fatigue, gastrointestinal, hematological, respiratory, and nervous system issues (somnolence, peripheral neurological disorders, dizziness, hypoaesthesia, paraesthesia, headache), and pyrexia were the side events that occurred the most frequently. The dose-limiting side effect of nelarabine treatment is neurotoxicity. An overdose of Nelarabine has no known cure. Supportive care should be offered following an acceptable clinical practice. So, it is necessary to take doses as prescribed by the doctors, and the emergence of any side effects must be reported as soon as possible. 

Atriance: Composition 

A clear, colorless solution is the Atriance solution for infusion. It comes in transparent glass vials with rubber stoppers covered by aluminum caps. Nelarabine is an active chemical. 5 mg of Nelarabine is contained in each milliliter of Atriance solution for infusion. There are 250 mg of Nelarabine in each vial. The additional ingredients include sodium hydroxide, water for injection, hydrochloric acid, and sodium chloride ( "Atriance contains sodium").

This antineoplastic drug is available in the market and can be purchased at budgeted rates as the Nelarabine injection price is economical. Visit us at https://www.indianpharmanetwork.in/ to know more about the drug. 

Atriance: Mechanism of Action 

A pro-drug of the deoxyguanosine analogue ara-G is Nelarabine. Adenosine deaminase (ADA) quickly demethylates Nelarabine to ara-G, which is subsequently intracellularly phosphorylated by deoxyguanosine and deoxycytidine kinase to yield Nelarabine's 5'-monophosphate metabolite. The active 5'-triphosphate form, ara-GTP, is subsequently created from the monophosphate metabolite. As ara-GTP builds up in leukemic blasts, it is preferentially incorporated into deoxyribonucleic acid (DNA), inhibiting DNA synthesis. Cells die as a result of this. Nelarabine injection cytotoxic effects could be mediated by several pathways. T-cells are more vulnerable to the cytotoxic effects of Nelarabine in vitro than B-cells. 

Atriance: Warnings And Precautions 

Although Atriance price is economical, there are some warnings and precautions associated with Atriance injection- 

• Nelarabine use has been associated with severe neurological responses. These reactions have included peripheral neuropathy, hypoesthesia, which can range from numbness and paresthesias to motor weakness and paralysis, altered mental states like severe somnolence, confusion, and coma, and effects on the central nervous system like convulsions, ataxia, and status epilepticus. 
• Ascending peripheral neuropathies resembling Guillain-Barré Syndrome and reactions linked to demyelination have also been reported. (Refer to section 4.8). 
• Nelarabine's dose-limiting hazard is neurotoxicity. Nelarabine withdrawal has not always resulted in complete recovery from these responses. Nelarabine must be stopped at the first indication of neurological reactions of NCI CTCAE Grade 2 or above, making close monitoring for neurological reactions highly advised. 

Atriance: Drug Interactions 

The key hepatic CYP isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 were not appreciably inhibited by Nelarabine or ara-G in vitro. It is not advised to provide nelarabine and adenosine deaminase inhibitors like pentostatin concurrently. Nelarabine's effectiveness may be decreased by concurrent administration, and either active substance's adverse event profile may be altered. 

When the drug is used by following the details provided by the health practitioner, it can be proven useful. For more detail about Nelarabine price, you can visit us at 

Indian Pharma Network does not provide narcotics or sedatives, only medications requiring a licensed physician's prescription. 

Managed Access Program (MAP)

A Managed Access Program (MAP) is a framework that provides patients with access to investigational or unapproved or unlicensed drugs outside of any clinical trials. These programs, sometimes referred to as Named Patient Programs (NPP), Expanded Access Programs (EAP), Compassionate Use Programs, or Early Access Programs, are designed to help those who have exhausted all existing treatment options and are unable to participate in any clinical trials. The primary goal of MAPs is to offer potentially life-saving or life-improving therapies to those with serious or life-threatening conditions.

There are several reasons for implementing a Managed Access Program (MAP) or Named Patient Program (NPP), including:

Addressing Unmet Medical Needs: MAPs help those with severe or life-threatening conditions who have no other existing treatment options or have failed to respond to existing therapies.

Limited Availability of Clinical Trials: Some patients may not be eligible for clinical trials because of strict inclusion and exclusion criteria or lack of trial availability in their region.

Gathering Additional Data: In some cases, data collected from patients in a MAP can supplement clinical trial data and provide valuable information on the safety and efficacy of a drug in a broader population.

Regulatory Compliance: MAPs are often conducted as per regulatory guidelines and can be an important step toward obtaining regulatory approval for a new medicine.

Ethical Considerations: Providing access to investigational medicines for those with no other options can be seen as an ethical obligation for pharma companies, especially when there is preliminary evidence of potential benefit.

Apart from this, there are also certain challenges and limitations linked with Managed Access Programs (MAPs):

Limited Drug Supply: The existence of investigational medicine may be limited, making it difficult to provide access to all eligible patients.

Financial Considerations: The cost of manufacturing and distributing investigational medicines can be high, and reimbursement for these costs may not always be available.

Uncertainty About Safety and Efficacy: Since the medicine has not yet been completely tested and approved, there is inherent uncertainty about its safety and efficacy.

Impact on Clinical Trial Enrolment: Offering access to an investigational medicine outside of clinical trials could potentially scale down the number of patients enrolling in the trials, which could be responsible for delaying the medicine approval process.

Despite all these challenges, Managed Access Programs remain an important mechanism for providing access to potentially beneficial therapies for those with serious or life-threatening conditions who have exhausted all other treatment options.

The “Indian Pharma Network (IPN) Managed Access” terminology covers all locally defined pre-approval access mechanisms and programs such as “Named Patient Supply”, “Compassionate Use”, “Expanded Access”, “Special Access /Programs”, and others.

How One Can Submit a Request for These Programs: A request for these programs (NPP/MAP) must be submitted by the treating doctor on behalf of the respective patient. All requests can be submitted either via our TOLL-FREE Number: 1800-889-1064 or Call/WhatsApp: +91 9310090915. Each request will be acknowledged promptly, and reviewed precisely by the appropriate IPN member with each and every effort made to provide a response quickly once we have all the required information. Please note that your request for this program will be evaluated in consideration of applicable local laws and regulations.